Expertise in
2
conditions

Elizabeth R. Plummer

Framlington Place, 
Newcastle Upon Tyne, ENG, GB 
Expertise in
2
conditions
Framlington Place, 
Newcastle Upon Tyne, ENG, GB 

Overview

Elizabeth Plummer practices practicing medicine in Newcastle Upon Tyne, United Kingdom.

Ms. Plummer is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Ataxia-Telangiectasia, Telangiectasia, Transient Erythroblastopenia of Childhood, and Aase Syndrome.

She is actively involved in clinical research, co-authoring 8 peer reviewed articles and participating in 6 clinical trials.

Gender

Female

Locations

Framlington Place, Newcastle Upon Tyne, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients With Advanced Solid Tumours
A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients With Advanced Solid Tumours
Enrollment Status: Completed
Publish Date: September 26, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer
A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer
Enrollment Status: Completed
Publish Date: June 22, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer
A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer
Enrollment Status: Completed
Publish Date: June 18, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Cancer Research UK Phase I Trial of AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1) in Patients With Advanced Cancer
A Cancer Research UK Phase I Trial of AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1) in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: April 11, 2022
Intervention Type: Drug
Study Drug: AZD3965
Study Phase: Phase 1
View 5 Less Clinical Trials

8 Total Publications

Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders.
Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders.
Journal: Journal of cancer research and clinical oncology
Published: June 23, 2023

Frequently Asked Questions about Elizabeth R. Plummer

Is Elizabeth R. Plummer a top-rated expert for Ataxia-Telangiectasia?

MediFind is an objective health platform that identifies experts based on real-world data. Elizabeth R. Plummer is classified as an Advanced expert for Ataxia-Telangiectasia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Elizabeth R. Plummer participate in research or clinical trials?

Yes. Elizabeth R. Plummer has published 8 articles and abstracts on conditions like Ataxia-Telangiectasia. You can view a list of Elizabeth R. Plummer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Plummer's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile